Urology News and Research

Latest Urology News and Research

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Discovery of cells responsible for bladder cancer spread

Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth. The findings, reported in the July Stem Cells, could help scientists develop new ways of finding and attacking similar cells in other types of cancer.

6 Aug 2009

Seed implants suitable prostate cancer treatment for men of all ages

Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient.

3 Aug 2009

Researchers investigate high-risk populations for bladder-cancer screenings

A new study by UT Southwestern Medical Center researchers sheds light on the challenges involved in identifying which high-risk population would benefit most from bladder-cancer screening.

16 Jul 2009

AbbeyMoor receives approval for design improvements to ‘The Spanner’ prostatic stent

AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner Prostatic Stent.

7 Jul 2009

Vibrator use during sex is common, linked to sexual health

Two Indiana University studies conducted among nationally representative samples of adult American men and women show that vibrator use during sexual interactions is common, with use being reported by approximately 53 percent of women and 45 percent of men ages 18 to 60. Not only is vibrator use common, but the two studies also show that vibrator use is associated with more positive sexual function and being more proactive in caring for one's sexual health.

30 Jun 2009

Urologist reports success using robot-assisted surgery for rare condition

Robot-assisted surgery can be used to successfully repair abnormal openings between the uterus and the bladder, according to a report by Ashok K. Hemal, M.D., a Wake Forest University Baptist Medical Center urologist who is the world's most experienced surgeon in the procedure.

23 Jun 2009

Search for prostate cancer biomarkers continues

Collaboration in prostate cancer translational research in Europe is not only vital to sustain the progress achieved in recent years but also to streamline current efforts between researchers and clinicians and avoid duplication or overlaps. This was amongst the goals of the two-day Prostate Cancer Translational Research in Europe (PCTRE) Meeting which opened today in Amsterdam, The Netherlands.

23 Jun 2009

New perspective on the causes, effects and potential treatment of sexual dysfunction

Couples' treatment for sexual problems and other innovative approaches to improving sexual health for men and women are on the agenda of sexual medicine experts.

23 Jun 2009

Bariatric surgery raises kidney stone risk

The most popular type of gastric bypass surgery appears to nearly double the chance that a patient will develop kidney stones, despite earlier assumptions that it would not, Johns Hopkins doctors report in a new study. The overall risk, however, remains fairly small at about 8 percent.

17 Jun 2009

Light therapy as a treatment for sexual dysfunctions

Although we are still far from knowing exactly where and how the pineal suppressive role is exerted, the fact that the gland exerts an inhibitory function on the reproductive axis is widely accepted. In fact, the pineal seems to exert its hormonal effect at different levels of the reproductive axis, both at the hypothalamic-pituitary level and at the gonadal level, where melatonin receptors have also been found.

9 Jun 2009

Gene activity reveals dynamic stroma microenvironment in prostate cancer

As stroma - the supportive framework of the prostate gland - react to prostate cancer, changes in the expression of genes occur that induce the formation of new structures such as blood vessels, nerves and parts of nerves, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Clinical Cancer Research.

9 Jun 2009